Aerosol composition comprising formoterol

Abstract

The use of a dry powder comprising (A) formoterol, or a pharmaceutically. acceptable salt or solvate thereof, or solvate of said salt, and (B) a pharmaceutically acceptable particulate diluent or carrier in an amount of from 400 μg to 5000 μg per μg of (A) for the preparation of an inhalable medicament for the treatment of chronic obstructive pulmonary disease.

1 - 11 . (canceled)  
     
     
         12 . A method of treating chronic obstructive pulmonary disease consisting essentially of administering by inhalation to a subject in need of such treatment an effective amount of a dry powder comprising (A) formoterol, or a pharmaceutically acceptable salt or solvate thereof, or solvate or said salt, and (B) a pharmaceutically acceptable particulate diluent or carrier in an amount of 400 μg to 5,000 μg per μg of (A), and said formoterol is the only active ingredient.  
     
     
         13 . A method according to  claim 12 , in which the formoterol (A) is in the form of formoterol fumarate dihydrate.  
     
     
         14 . A method of treating chronic obstructive pulmonary disease which comprises administering by inhalation to a subject in need of such treatment an effective amount of a dry powder consisting, or consisting essentially, of (A) formoterol fumarate dihydrate and (B) a pharmaceutically acceptable diluent or carrier in an amount from 400 μg to 5,000 μg per μg of (A).  
     
     
         15 . A method according to  claim 14 , in which the diluent or carrier (B) is a saccharide, a sugar alcohol or a mixture thereof.  
     
     
         16 . A method according to  claim 15 , in which the diluent or carrier (B) is lactose.  
     
     
         17 . A method according to  claim 14 , in which the diluent or carrier (B) is present in an amount of 800 to 3000 μg per μg of (A).  
     
     
         18 . A method according to  claim 14 , in which the dry powder is in a capsule, the capsule containing a unit dose of (A).  
     
     
         19 . A method according to  claim 18 , in which the capsule contains 12 μg of (A) and 19988-24988 μg of diluent or carrier (B).  
     
     
         20 . A method according to  claim 14 , in which the dry powder is in a reservoir of a multi-dose dry powder inhaler adapted to deliver a unit dose of (A) per actuation.